Table 3. Odds ratios (OR) for Kaposi's sarcoma according to the latent (seropositive vs seronegative) and lytic (seropositive vs seronegative/indeterminate) anti-KSHV antibody status, stratified by the time between first sample collection and diagnosis of cancer.
|
Unadjusted
|
Adjusted for CD4 counta
|
|||||
|---|---|---|---|---|---|---|
| Time between sample collection and diagnosis of Kaposi's sarcoma | No. of case–control pairs (total=189) | No. of seropositive cases/controls | OR (95% CI) | No. of case–control pairs (total=163) | No. of seropositive cases/controls | Adjusted OR (95% CI) |
| Latent anti-KSHV antibodies | ||||||
| <14 months | 62 | 23/4 | 7.3 (2.2–24.5) | 38 | 16/3 | 5.0 (1.4–18.5) |
| 14–42 months | 67 | 26/9 | 3.8 (1.6–9.4) | 65 | 25/8 | 4.1 (1.5–11.4) |
| >42 months | 60 | 23/10 | 4.3 (1.4–12.6) | 60 | 23/10 | 4.1 (1.4–12.4) |
| χ2(1)=0.4, P=0.6 | χ2(1)=0.04, P=0.8 | |||||
|
Unadjusted
|
Adjusted for CD4 counta
|
|||||
|---|---|---|---|---|---|---|
| Time between sample collection and diagnosis of Kaposi's sarcoma | No. of case–control pairs (total=187) | No. of seropositive cases/controls | OR (95% CI) | No. of case–control pairs (total=161) | No. of seropositive cases/controls | Adjusted OR (95% CI) |
| Lytic anti-KSHV antibodies | ||||||
| <14 months | 60 | 16/6 | 2.7 (1.0–6.8) | 36 | 11/4 | 3.9 (0.9–16.1) |
| 14–42 months | 67 | 17/11 | 1.8 (0.7–4.2) | 65 | 17/10 | 2.6 (0.9–7.5) |
| >42 months | 60 | 11/9 | 1.3 (0.5–3.5) | 60 | 11/9 | 1.4 (0.5–3.9) |
| χ2(1)=1.1, P=0.3 | χ2(1)=1.4, P=0.2 | |||||
a
Adjusted for CD4 count (<200, 200–500, 500+); the number of participants is fewer because some did not have a CD4 count available from around the time the blood was collected.